New hope for tough leukemia: adding a targeted drug to standard chemotherapy
NCT ID NCT05453500
Summary
This study is testing if adding a targeted drug called tafasitamab to a standard chemotherapy regimen works better for treating adults with a specific type of acute lymphoblastic leukemia (B-ALL). The trial aims to see if this combination can more effectively kill cancer cells and reduce the amount of leftover disease after treatment. It is for adults newly diagnosed with this cancer who may not be good candidates for other intensive treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.